Mansukh Mandaviya inaugurates 27 bulk drug park projects, manufacturing plants for medical devices

New Delhi [India], March 2 : Union Health Minister Dr Mansukh Mandaviya virtually inaugurated 27 greenfield bulk drug park projects and 13 greenfield manufacturing plants for medical devices here on Saturday.
Addressing the gathering, Union Minister for Chemicals and Fertilizers and Health and Family Welfare, Dr Mandaviya said, "Medicines are an essential requirement for any society. During the COVID-19 pandemic, the dangers of supply chain getting affected, the risks of being highly dependent on imports of critical resources like bulk drugs and medical devices, and its potential effects on India's pharma and MedTech sectors led to a lot of brainstorming within the Union Government. The production-linked incentive (PLI) scheme is a result of these wide-ranging discussions."
Expressing his elation at the inauguration of these greenfield projects under the PLI scheme, the Union Minister said, "It is noteworthy that today India has not only reduced its dependence on medicines, API and medical devices, the country is also emerging as a major exporter of these products, thanks to the success of the PLI scheme."
Dr Mandaviya said, "The PLI-I scheme of the Union Government identified 48 critical bulk drugs for manufacturing locally. The success of this inaugural scheme led the government to launch the Rs. 15,000 crore PLI-II scheme, which envisaged increasing our cost competitiveness for medicines and medical products in the international market."
Highlighting the Union Government's efforts towards making India atmanirbhar in the field of critical medicines and active pharmaceutical ingredients (API), the Union Minister stated the example of Penicillin G, a widely used drug that were locally manufactured in India until the late 1980s. Due to globalization, the import of Penicillin G led to the closure of all such plants in India. He highlighted that the Union Government is working on bringing back production of Penicillin G in India after three decades.
Rajesh Kumar Singh, Secretary, Dept. for Promotion of Industry and Internal Trade noted that Union Government approached the COVID-19 pandemic with a mindset to turn the crisis into an opportunity. He highlighted the efforts of the administration in enhancing self-reliance, innovation and infrastructure, including both physical and digital, as displays of such a vision.
Dr. Arunish Chawla, Secretary; Dept. of Pharmaceuticals, gave a detailed presentation on the PLI scheme of the Union Government. He said that the drug and pharmaceutical industry in India witnessed a 12% compound annual growth rate (CAGR) in the last 10 years.
It was also informed that when the PLI scheme came in, India imported 90 per cent of medical devices. After the introduction of the PLI scheme, the net imports of medical devices decreased for the first time in 2023.